Get started
NOVAVAX INCNOVAVAX INCNOVAVAX INC

NOVAVAX INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NVAX trade ideas

NVAX - Break OutAfter MRNA , PFE , AZE's great vaccine trial result, the group has gained momentum today. The market is optimistic about NVAX's coming result and pushed price above pivot $113. The 4 month correction of 59% is finished and there is a chance for NVAX to challenge previous high at $188 if the vaccine result is good. However, it is a risky bet since the vaccine trial result is not out yet. Should buy with cautious. My recommendation is to limit risk by using bull spread strategy. For example: buy $135 call @ $11 + Sell $165 call @ $5 with total cost of $6; The max profit is $2400 and max loss is $600 Or buy the stock at $120 with SL at $100 and 1st TP at $150, 2nd PT at $188.
NASDAQ:NVAXLong
by FinTasticTrading
$NVAX Bearish Swing Trade PlanGreen Line - Entry Target Red Line - Exit Target Pink Line - Stop-Loss Highly suggest using Google to Search "Transparent Traders" if you're trying to get to the next level. Transparent Traders exists to solve the critical issues facing our traders, both large and small. Our unique approach is not only what differentiates us, but also what makes us successful. Our advanced Blackbox uses custom algorithms & predictive A.I. to locate the most accurate day or swing trades for the best chance of success.
NASDAQ:NVAXShort
by jonny_red32
NVAX earnings miss (-$3.21 / share)Novavax (NVAX) reported a 3rd Quarter September 2020 loss of $3.21 per share on revenue of $157.0 million. The consensus earnings estimate was $2.36 per share on revenue of $234.2 million. I won't be surprised if NVAX tanks below $50 by 11/20. Do your own due diligence, your risk is 100% your responsibility. Good luck and happy trading friends... *3x lucky 7s of trading 101* 7pt Trading compass: Price action Volume average Trend momentum Current events Revenue & Earnings Debt / Cash Book value 7 Common mistakes: +5% portfolio trades Bad risk management Emotions & Opinions FOMO Lack of planning & discipline Forgetting restraint Repetitive errors 7 Important tools: Trading View app Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big organized desk Reading books Brokerage UI Checkout my indicators: Fibonacci VIP - volume Fibonacci MA7 - price www.tradingview.com
NASDAQ:NVAXShort
by Options360
6
NVAX STOCKS DUMPED, DOWNTREND CONTINUESEarlier this year there was the question : How do you invest in Coronavirus vaccine stocks? Now, we have the answer : YOU DONT. Chart looking bleak, and the support lines are weak. This could be due to a few reasons: - Lack of MAINSTREAM updates - NVAX actually has no other vaccines - Market volatility due to covid and elections - Investors are seeking less riskier gains and getting out of stocks that do not look promising Other than the above, we have seen strange behavior with stocks of companies in the race. A few examples: PFE Pfizer stock not responding to numerous huge injections from government REGN Regeneron stocks hardly responding to Trump pimp GILD Gilead even FALLING after being the first company world wide to receive FDA approval for remdesivir as a treatment. AZN Astrazeneca in conjunction with Oxford has a trail candidate dead but stocks remain largely unaffected I think NVAX has potential in the long run, long term I remain bullish for the company fundamentally, but not for an investment choice right now. In fact I'd say that no vaccine stock is a good investment right now. The way the market reacts to news is too unpredictable and the future remains uncertain. Hit like if you found this insightful and helpful Thanks, Ev
NASDAQ:NVAX
by BlockTechEv
1
NVAX to Head Higher in the Coming Weeks?This is the first tap of the original low outside of a major trend break. It is also the 11.4 fib level of the breakout move. With price ranging between $87-$126, I'd expect for $126 to be tested again. We do have several catalyst coming down the pipeline as well. Phase 2 results, Phase 3 results, EU Deal is still in limbo, FDA approval, then actual sales of the vaccine if approved. With this pattern, I'm expecting a sharp V correction into new highs. We'll see.
NASDAQ:NVAXLong
by allout06
NVAX earnings 11/09 4pm, target $175 by 11/10Let's start with, I have a love / hate relationship with NVAX. lol. It all began when I bought shares on 5/28/19, 5/30/19, 7/3/19 & 7/16/19 for 5.97, 5.71, 5.41 & 4.64 respectively. Nobody could have predicted what 2020 had in store for all of us. Like the Grateful Dead album, "What a long strange trip it's been". So it goes without saying, I just can't wrap my head around buying anymore shares of NVAX in the the double digits, let alone triple digits, the past 6 months. With that said, there's way more people out there that don't have my avoidance in investing in NVAX at these levels. As far as their NVX-CoV2373 covid-19 vaccine (credit: novavax.com), I think it's the most serious candidate out there. If the data of their Phase 2 clinical trials that started in August, are revealed before or during Q3 earnings and it's a positive result, my target is $175. The technicals show a consolidation with price spreads tightening, with higher lows the past month. So all in all, I'm bullish heading into November. Good luck and happy trading friends...
NASDAQ:NVAX
by Options360